Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome

Werner's Syndrome Clinical Trial

Status Completed

Clinical Trial Summary

OBJECTIVES:

I. Assess the safety and efficacy of recombinant human insulin-like growth factor 1 in a patient with Werner's syndrome and osteoporosis.

Clinical Trial Description

PROTOCOL OUTLINE: The patient receives subcutaneous recombinant human insulin-like growth factor 1 daily for 7 months. The dose is adjusted according to the serum hormone level and biological markers of bone turnover.

Concurrent therapy includes a metabolic diet, calcium citrate, and estradiol. ;

Study Design

Allocation: Non-Randomized, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Syndrome
• Werner Syndrome
• Werner's Syndrome

• NCT number: NCT00004815
• Study type: Interventional
• Source: Office of Rare Diseases (ORD)
• Status: Completed
• Phase: N/A
• Start date: May 1992